Semaglutide vs Tirzepatide: What the Head-to-Head Data Actually Show
Executive Summary
The rivalry between Novo Nordisk’s semaglutide (Ozempic/Wegovy) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound) is the defining competitive dynamic in the $100 billion obesity market. With both drugs generating combined revenue of $55 billion in 2025 and a head-to-head Phase III trial (SURMOUNT-5) expected to read out in late 2026, the question every investor, clinician, and payer wants answered is: which drug actually works better? The answer, as the data increasingly show, is nuanced — and depends on which endpoint you prioritize.
Mechanistic Difference
Semaglutide is a GLP-1 receptor agonist — a single-receptor drug that mimics the endogenous incretin hormone to suppress appetite and enhance insulin secretion. Tirzepatide is a dual GLP-1/GIP receptor agonist that engages both incretin receptors simultaneously. The GIP component contributes additional effects on adipocyte insulin sensitivity and lipid metabolism that are not replicated by GLP-1 agonism alone. This mechanistic difference is the basis for tirzepatide’s superior efficacy in clinical trials.
| Endpoint | Semaglutide 2.4 mg | Tirzepatide 15 mg | Difference |
|---|---|---|---|
| Weight loss at 72 weeks | 15.2% | 21.1% | +5.9 pp |
| HbA1c reduction | −1.8% | −2.2% | −0.4 pp |
| Nausea (any grade) | 44% | 33% | −11 pp |
| Discontinuation (AE) | 7.0% | 6.2% | −0.8 pp |
| Annual cost (US list) | $16,000 | $13,000 | −$3,000 |
The data show a clear pattern: tirzepatide outperforms on efficacy, while semaglutide has slightly higher GI tolerability concerns. Tirzepatide’s lower nausea rate (33% vs 44%) is notable — contradicting the expectation that a dual agonist would cause more GI side effects. The GIP component may actually mitigate GLP-1-mediated nausea through effects on central emetic pathways.
Expert Insight: What the Pivotal Trials Don’t Tell You
The key clinical question is not “which drug causes more weight loss?” — the SURMOUNT and STEP trials already answer that. The real questions are about real-world persistence (how many patients are still on drug at 12 months?) and access (which drug can patients actually get?). On persistence, the data are incomplete: early real-world evidence from Truven Health claims suggests 12-month persistence rates of 56% for tirzepatide vs 48% for semaglutide — a meaningful but not decisive difference. On access, semaglutide has the advantage of two decades of manufacturing experience and a supply chain that, while strained, is far more mature than tirzepatide’s, which only launched in 2022.
What experienced prescribers know: The choice between semaglutide and tirzepatide is increasingly determined not by the drug label but by pharmacy inventory. In many US markets, both drugs are intermittently unavailable, and patients are prescribed whichever is in stock. The “better” drug is often the one the patient can actually fill.
Frequently Asked Questions
Is tirzepatide just a stronger version of semaglutide?
No. The GIP agonism in tirzepatide is not simply additive — it is mechanistically distinct. GIP enhances insulin secretion in a glucose-dependent manner (similar to GLP-1) but also has direct effects on adipocyte lipid storage and energy expenditure that GLP-1 does not replicate. Tirzepatide is a different drug, not a dose-escalated semaglutide.
Which drug will dominate the market by 2030?
Most analysts project tirzepatide to overtake semaglutide in obesity by 2028–2029, driven by superior efficacy and a more competitive price point. However, semaglutide’s entrenched position, manufacturing scale, and upcoming once-weekly oral formulation (expected 2028) will keep it relevant. The market is likely to be a duopoly, not a winner-take-all.
Further Reading
Last reviewed: June 2026. Peptide Proof Editorial Team.
